Literature DB >> 20111630

The impact of prostate cancer and hormonal therapy on bone.

Gerald L Andriole1.   

Abstract

Large-scale studies agree that the observed decline in prostate cancer mortality that began in the early 1990s, shortly after prostate-specific antigen testing was introduced in the United States, is most likely explained by more widespread treatment of prostate cancer, including hormonal therapy. Practitioners should be aware of the risk of the development of osteoporosis and of skeletal side effects related to hormonal therapy to optimize the care of men with prostate cancer.

Entities:  

Keywords:  Androgen deprivation therapy; Bone destruction; Hormone deprivation therapy; Osteopenia; Osteoporosis

Year:  2009        PMID： 20111630      PMCID： PMC2809985     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  27 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

3.  Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.

Authors:  Susan L Greenspan; Penelope Coates; Susan M Sereika; Joel B Nelson; Donald L Trump; Neil M Resnick
Journal:  J Clin Endocrinol Metab       Date:  2005-09-27       Impact factor: 5.958

4.  Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.

Authors:  Juan Morote; Jacques Planas Morin; Anna Orsola; Jose M Abascal; Carles Salvador; Enrique Trilla; Carles X Raventos; Lluis Cecchini; Gloria Encabo; Jaume Reventos
Journal:  Urology       Date:  2007-03       Impact factor: 2.649

5.  Osteoporosis after orchiectomy for prostate cancer.

Authors:  H W Daniell
Journal:  J Urol       Date:  1997-02       Impact factor: 7.450

6.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

7.  Mortality following the diagnosis of a vertebral compression fracture in the Medicare population.

Authors:  Edmund Lau; Kevin Ong; Steven Kurtz; Jordana Schmier; Av Edidin
Journal:  J Bone Joint Surg Am       Date:  2008-07       Impact factor: 5.284

8.  Comparison of drug adherence rates among patients with seven different medical conditions.

Authors:  Becky A Briesacher; Susan E Andrade; Hassan Fouayzi; K Arnold Chan
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.

Authors:  Anthony V D'Amico; James W Denham; Juanita Crook; Ming-Hui Chen; Samuel Z Goldhaber; David S Lamb; David Joseph; Keen-Hun Tai; Shawn Malone; Charles Ludgate; Allison Steigler; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2007-06-10       Impact factor: 44.544
View more
  4 in total

1.  Optimization and Characterization of a Bone Culture Model to Study Prostate Cancer Bone Metastasis.

Authors:  Yi-Hsuan Wu; Zbigniew Gugala; Megan M Barry; Yichao Shen; Subhamoy Dasgupta; Hai Wang
Journal:  Mol Cancer Ther       Date:  2022-08-02       Impact factor: 6.009

Review 2.  Bone Tropism in Cancer Metastases.

Authors:  Hai Wang; Weijie Zhang; Igor Bado; Xiang H-F Zhang
Journal:  Cold Spring Harb Perspect Med       Date:  2020-10-01       Impact factor: 5.159

3.  Bioelectrical Impedance Vector Pattern and Biomarkers of Physical Functioning of Prostate Cancer Survivors in Rehabilitation.

Authors:  Alexander Stäuber; Marc Heydenreich; Peter R Wright; Steffen Großmann; Niklas Grusdat; Dirk-Henrik Zermann; Henry Schulz
Journal:  Rehabil Process Outcome       Date:  2021-12-16

4.  Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells.

Authors:  Abhilash Samykutty; Aditya V Shetty; Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram; Gouxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla; Munirathinam Gnanasekar
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-24       Impact factor: 2.629
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.